About Alpha Innotech
Alpha Innotech is a genomic tools company providing signal detection, digital imaging and application support to the Life Science markets. Our new modular technology platforms combine instruments, reagents and bioinformatics to offer integrated solutions for functional genomics and gene expression analysis. Our goal is to provide innovative and high performance tools to accelerate genetic discovery. Alpha Innotech Corporation offers innovative products in the following markets: Life Science Research: We develop and market genetic analysis tools that are used for digital imaging, image documentation, quantitative analysis, gene expression studies and a wide range of other Life Science applications. Our goal is to bring technology and applications together to provide turnkey solutions. OEM/Custom Projects: Utilizing our core technologies in digital imaging, we offer customized solutions in diagnostics, high throughput screening, and laboratory automation.
Missing: Alpha Innotech's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Alpha Innotech's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Alpha Innotech
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Alpha Innotech is included in 1 Expert Collection, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Alpha Innotech Frequently Asked Questions (FAQ)
When was Alpha Innotech founded?
Alpha Innotech was founded in 1992.
Where is Alpha Innotech's headquarters?
Alpha Innotech's headquarters is located at 2401 Merced Street, San Leandro.
What is Alpha Innotech's latest funding round?
Alpha Innotech's latest funding round is Acquired.
How much did Alpha Innotech raise?
Alpha Innotech raised a total of $8.88M.
Who are the investors of Alpha Innotech?
Investors of Alpha Innotech include ProteinSimple, Emerging Technology Center, Vivo Capital and Kenson Ventures.
Who are Alpha Innotech's competitors?
Competitors of Alpha Innotech include Sesen Bio, BioDot, Scienion, BioGX, Amnis Corporation, WaferGen Bio-systems, ZyGEM, HTG Molecular Diagnostics, CareDx, Evogen and 28 more.
Compare Alpha Innotech to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.
SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.
Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.
Intelligent Medical Devices, dba IntelligentMDx, develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Its aim is to translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to improve patient care.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.